USA-based Kailera Therapeutics today announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions. 1 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
USA-based Kailera Therapeutics today announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions. 1 October 2024
Boston, USA-based biotech Aktis Oncology, which is targeting alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced the successful closing of an oversubscribed and upsized $175 million Series B financing. 1 October 2024
Chicago, USA-based ARCH Venture Partners revealed it has closed the ARCH Venture Fund XIII, a venture capital fund with more than $3 billion to support the founding and growth of early-stage biotechnology companies. 27 September 2024
USA-based biotech funder and incubator Flagship Pioneering yesterday unveiled Mirai Bio, a company pioneering the first open end-to-end platform for the biotech industry to enable the co-creation of fully optimized genetic medicines. 27 September 2024
The UK government has released a position paper outlining its vision for Framework Programme 10 (FP10), a successor to Horizon Europe, the EU's flagship research collaboration program. 26 September 2024
Italian biotech Genespire—which is developing off-the-shelf gene therapies for pediatric patients affected by genetic diseases—has announced the closing of a 46.6 million euros ($52 million) Series B financing. 25 September 2024
Healthcare plan provider Centivo has raised $75 million in equity and debt financing to support its goal of offering affordable care to employees and their families. 25 September 2024
Rare disease firm bluebird bio has announced a company-wide restructuring aimed at cutting costs by 20% and achieving quarterly cash flow break-even by the second half of 2025. 25 September 2024
Aptadir Therapeutics, a biotech company focused on RNA inhibitor-based therapies for cancer and genetic conditions, has launched with $1.6 million in pre-seed funding. 24 September 2024
Australian biotech company Telix Pharmaceuticals is to acquire USA-based RLS Radiopharmacies, expanding its manufacturing and distribution footprint in North America. 24 September 2024
British biotech Vicebio has secured $100 million in a series B funding round to accelerate the development of its next-generation vaccines against respiratory viruses. 23 September 2024
Nordic biotech firm Swedish Orphan Biovitrum has seen its 2nd-qtr 2016 sales reach levels 92% higher than the same period last year, with the latest results sending its share price up by nearly 8% on Friday. 15 July 2016
Teva Pharmaceutical Industries will raise between $20 billion and $25 billion in a multi-currency bond sale to pay for its $40.5 billion acquisition of the generics business of Ireland-incorporated company Allergan. 15 July 2016
Reports have linked Indian drugmaker Aurobindo to buying European assets of Israeli generics giant Teva Pharmaceutical Industries, with talk of a deal worth as much as $1.5 billion. 7 July 2016
Investment research firm Edison has raised its valuation on German specialty pharma company Paion but decreased the earnings per share (EPS) assessment after the out-licensing of certain rights to Italian drugmaker Cosmo Pharmaceuticals. 6 July 2016
A rapidly growing biotechnology industry in China could see the country discovering and developing its own new chemical entities (NCEs) within the next five years, a report has said. 2 July 2016
Australia's Mayne Pharma has propelled itself into one of the top 25 generics sellers in the USA by joining in the buy-up of assets from Israel’s Teva Pharmaceutical Industries and Ireland-incorporated Allergan. 29 June 2016
UK-based Sinclair Pharma has had some hugely challenging decisions to make as it has undergone a strategic review over the last 18 months. 25 June 2016
USA-based Impax Laboratories has become the latest company to buy up assets being sold by Israeli generics giant Teva Pharmaceutical Industries in a $586 million deal. 21 June 2016
India’s Zydus Cadila has added to its US portfolio by buying two new Abbreviated New Drug Applications (ANDAs) from Israeli generics giant Teva Pharmaceutical Industries in an undisclosed transaction. 20 June 2016
US specialty drugmaker Sagent Pharmaceuticals has agreed to buy five products being developed by Israeli generics giant Teva Pharmaceutical Industries. 17 June 2016
The man brought in to turn around the fortunes of Valeant Pharmaceuticals after a disastrous period for the company, has said that its 1st-qtr financial results reflect the “significant disruption this organization has faced over the past few months.” 8 June 2016
Belgian drug developer Ablynx has raised 74.2 million euros ($82.8) through a private placement of new shares via an accelerated book building procedure announced on Wednesday. 2 June 2016
US-based Ariad Pharmaceuticals will pocket $25 million in second quarter net product revenue related to cumulative shipments of its leukemia treatment Iclusig (ponatinib) to France, following talks with the French health authorities. 20 May 2016
Danish biotech firm Bavarian Nordic has announced a $100 million contract for its Imvamune smallpox vaccine with a division of the US Department of Health and Human Services. 19 May 2016
German life sciences and pharma company Merck KGaA has increased its first-quarter 2016 sales and earnings following the acquisition of US-based pharma equipment maker Sigma-Aldrich. 19 May 2016
The assets of Israeli drugmaker Teva Pharmaceutical International in the UK, Ireland and Iceland have attracted interest from bidders including Netherlands-incorporated Mylan and Swiss pharma giant Novartis, Bloomberg reports. 16 May 2016
Japan’s largest drug company, Takeda Pharmaceutical, has recovered from losses the previous year to report increased sales and profits in its financial results for the fiscal year ending in March 2016. 11 May 2016
A pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases.
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news